Cipla's Pithampur unit gets 8 observations from USFDA after inspection

​​ The US Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from February 6 - 17, the Mumbai-based drug firm said in a regulatory filing. On conclusion of the inspection, the company has received 8 inspectional observations in Form 483, it added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y2XcekS
via IFTTT

0 comments:

Post a Comment